LY3437943 — Research Summary
Triple hormone receptor agonist (GLP-1/GIP/glucagon) studied for advanced metabo
LY3437943
An evidence summary of published preclinical research on LY3437943. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.
Molecular Data
Compound Overview
LY3437943 (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. It represents the next evolution beyond dual agonists like LY3298176 by adding glucagon receptor activation. It is an active subject of incretin-pathway receptor research.
Reported Mechanism (Preclinical)
LY3437943 activates three distinct glucagon-family receptors: GLP-1R (promoting satiety, insulin secretion, and slowed gastric emptying), GIPR (enhancing insulin sensitivity and fat metabolism), and GCGR (glucagon receptor, stimulating hepatic glycogenolysis, lipolysis, and thermogenesis). The glucagon component is the key differentiator — it increases energy expenditure and hepatic fat oxidation. The triple mechanism produces synergistic incretin-pathway effects exceeding dual agonists.
Mechanisms described above are reported in preclinical (animal and in vitro) literature and have not been established for human use.
Key Research Highlights
- Glucagon receptor agonism contributed to increased energy expenditure and thermogenesis
Published References
-
Triple-hormone-receptor agonist LY3437943 for obesity — a phase 2 trial
N Engl J Med, 2023 -
LY3437943, a GGG tri-agonist, for type 2 diabetes
N Engl J Med, 2023 -
GLP-1/GIP/glucagon triple receptor agonism: a new paradigm in obesity therapy
Lancet Diabetes Endocrinol, 2023
Available for Research
Lab-tested, third-party COA published, ships from the U.S.
View Product · LY3437943 View COA Library